Exploiting large-scale drug-protein interaction information for computational drug repurposing

BMC Bioinformatics

Volumn 15, Issue 1, 2014, Pages

  Liu, Ruifeng ^a   Singh, Narender ^a   Tawa, Gregory J ^a   Wallqvist, Anders ^a   Reifman, Jaques ^a  

^a U S ARMY MEDICAL RESEARCH AND MATERIEL COMMAND   (United States)

Author keywords

Bayes theorem; Drug repurposing; Drug protein interaction; Mechanism of drug action

Indexed keywords

DISEASES; DRUG THERAPY; FORECASTING; PROTEINS; VIRUSES;

BAYES THEOREM; CLASSIFICATION MODELS; DRUG ACTION; DRUG-PROTEIN INTERACTIONS; HUMAN IMMUNODEFICIENCY VIRUS; PHARMACEUTICAL RESEARCH AND DEVELOPMENT; REPURPOSING; THERAPEUTIC EFFECTS;

DRUG INTERACTIONS;

HUMAN IMMUNODEFICIENCY VIRUS;

PROTEIN;

ARTICLE; BAYES THEOREM; DRUG APPROVAL; DRUG INTERACTION; DRUG REPOSITIONING; HYPERTENSION; METABOLISM; METHODOLOGY; UNITED STATES;

BAYES THEOREM; DRUG APPROVAL; DRUG INTERACTIONS; DRUG REPOSITIONING; HYPERTENSION; PROTEINS; UNITED STATES;

EID: 84902739128     PISSN: None     EISSN: 14712105     Source Type: Journal    
DOI: 10.1186/1471-2105-15-210     Document Type: Article

References (54)

1. Paul SM, Lewis-Hall F. Drugs in search of diseases. Sci Transl Med 2013, 5(186):186fs118.
2. Drews J. Drug discovery: a historical perspective. Science 2000, 287(5460):1960-1964.
3. Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, Schacht AL. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Discov 2010, 9(3):203-214.
4. Sonner JM, Cantor RS. Molecular mechanisms of drug action: an emerging view. Annu Rev Biophys 2013, 42:143-167.
5. Ghofrani HA, Osterloh IH, Grimminger F. Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. Nat Rev Drug Discov 2006, 5(8):689-702.
6. Tobinick EL. The value of drug repositioning in the current pharmaceutical market. Drug News Perspect 2009, 22(2):119-125.
7. Teo S, Resztak KE, Scheffler MA, Kook KA, Zeldis JB, Stirling DI, Thomas SD. Thalidomide in the treatment of leprosy. Microb Infect Institut Pasteur 2002, 4(11):1193-1202.
8. Hicks LK, Haynes AE, Reece DE, Walker IR, Herst JA, Meyer RM, Imrie K, . Hematology Disease Site Group of the Cancer Care Ontario Program in Evidence-based C A meta-analysis and systematic review of thalidomide for patients with previously untreated multiple myeloma. Cancer Treat Rev 2008, 34(5):442-452. Hematology Disease Site Group of the Cancer Care Ontario Program in Evidence-based C.
9. Thalidomide Thalidomide: research advances in cancer and other conditions. http://www.mayoclinic.com/health/thalidomide/HQ01507, Thalidomide.
10. Wu JJ, Huang DB, Pang KR, Hsu S, Tyring SK. Thalidomide: dermatological indications, mechanisms of action and side-effects. Br J Dermatol 2005, 153(2):254-273.
11. Ito T, Ando H, Suzuki T, Ogura T, Hotta K, Imamura Y, Yamaguchi Y, Handa H. Identification of a primary target of thalidomide teratogenicity. Science 2010, 327(5971):1345-1350.
12. Kronke J, Udeshi ND, Narla A, Grauman P, Hurst SN, McConkey M, Svinkina T, Heckl D, Comer E, Li X, Ciarlo C, Hartman E, Munshi N, Schenone M, Schreiber SL, Carr SA, Ebert BL. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science 2014, 343(6168):301-305.
13. Lu G, Middleton RE, Sun H, Naniong M, Ott CJ, Mitsiades CS, Wong KK, Bradner JE, Kaelin WG. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science 2014, 343(6168):305-309.
14. Cheng F, Liu C, Jiang J, Lu W, Li W, Liu G, Zhou W, Huang J, Tang Y. Prediction of drug-target interactions and drug repositioning via network-based inference. PLoS Comput Biol 2012, 8(5):e1002503.
15. Dudley JT, Deshpande T, Butte AJ. Exploiting drug-disease relationships for computational drug repositioning. Brief Bioinform 2011, 12(4):303-311.
16. Dudley JT, Sirota M, Shenoy M, Pai RK, Roedder S, Chiang AP, Morgan AA, Sarwal MM, Pasricha PJ, Butte AJ. Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease. Sci Transl Med 2011, 3(96):96ra76.
17. Gottlieb A, Stein GY, Ruppin E, Sharan R. PREDICT: a method for inferring novel drug indications with application to personalized medicine. Mol Syst Biol 2011, 7:496.
18. Haupt VJ, Schroeder M. Old friends in new guise: repositioning of known drugs with structural bioinformatics. Brief Bioinform 2011, 12(4):312-326.
19. Hoehndorf R, Oellrich A, Rebholz-Schuhmann D, Schofield PN, Gkoutos GV. Linking PharmGKB to phenotype studies and animal models of disease for drug repurposing. Pac Symp Biocomput 2012, 17:388-399.
20. Iorio F, Bosotti R, Scacheri E, Belcastro V, Mithbaokar P, Ferriero R, Murino L, Tagliaferri R, Brunetti-Pierri N, Isacchi A, di Bernardo D. Discovery of drug mode of action and drug repositioning from transcriptional responses. Proc Natl Acad Sci U S A 2010, 107(33):14621-14626.
21. Moriaud F, Richard SB, Adcock SA, Chanas-Martin L, Surgand JS, Ben Jelloul M, Delfaud F. Identify drug repurposing candidates by mining the protein data bank. Brief Bioinform 2011, 12(4):336-340.
22. Napolitano F, Zhao Y, Moreira VM, Tagliaferri R, Kere J, Damato M, Greco D. Drug repositioning: a machine-learning approach through data integration. J Cheminform 2013, 5(1):30.
23. Pacini C, Iorio F, Goncalves E, Iskar M, Klabunde T, Bork P, Saez-Rodriguez J. DvD: An R/Cytoscape pipeline for drug repurposing using public repositories of gene expression data. Bioinformatics 2013, 29(1):132-134.
24. Jahchan NS, Dudley JT, Mazur PK, Flores N, Yang D, Palmerton A, Zmoos AF, Vaka D, Tran KQ, Zhou M, Krasinska K, Riess JW, Neal JW, Khatri P, Park KS, Butte AJ, Sage J. A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors. Canc Discov 2013, 3(12):1364-1377.
25. Kuhn M, Szklarczyk D, Franceschini A, von Mering C, Jensen LJ, Bork P. STITCH 3: zooming in on protein-chemical interactions. Nucleic Acids Res 2012, 40(Database issue):D876-D880.
26. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res 2011, 39(Database issue):D1035-D1041.
27. Keiser MJ, Roth BL, Armbruster BN, Ernsberger P, Irwin JJ, Shoichet BK. Relating protein pharmacology by ligand chemistry. Nat Biotechnol 2007, 25(2):197-206.
28. Xia X, Maliski EG, Gallant P, Rogers D. Classification of kinase inhibitors using a Bayesian model. J Med Chem 2004, 47(18):4463-4470.
29. Laplace Estimate. Encyclopedia of Machine Learning 2010, 571. US: Springer, Sammut C, Webb G.
30. List of Blood Pressure Drugs. http://www.nhlbi.nih.gov/hbp/treat/bpd_list.htm.
31. FDA-approved anti-HIV medications. http://aidsinfo.nih.gov/drugs.
32. Malaria treatment (United States). http://www.cdc.gov/malaria/diagnosis_treatment/treatment.html.
33. Li M, Yang M, Qiu X. The effect of nimodipine on retinal blood flow in pregnancy induced hypertension. Zhonghua Fu Chan Ke Za Zhi 1998, 33(7):397-399.
34. Bader JD, Bonito AJ, Shugars DA. A systematic review of cardiovascular effects of epinephrine on hypertensive dental patients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2002, 93(6):647-653.
35. del Real G, Jimenez-Baranda S, Mira E, Lacalle RA, Lucas P, Gomez-Mouton C, Alegret M, Pena JM, Rodriguez-Zapata M, Alvarez-Mon M, Martínez-A C, Mañes S. Statins inhibit HIV-1 infection by down-regulating Rho activity. J Exp Med 2004, 200(4):541-547.
36. Orlikowsky TW, Wang ZQ, Dudhane A, Dannecker GE, Niethammer D, Wormser GP, Hoffmann MK, Horowitz HW. Dexamethasone inhibits CD4 T cell deletion mediated by macrophages from human immunodeficiency virus-infected persons. J Infect Dis 2001, 184(10):1328-1330.
37. Harbison MA, Kim SY, Gillis JM, Hammer SM. Effect of the calcium channel blocker verapamil on human immunodeficiency virus type 1 replication in lymphoid cells. J Infect Dis 1991, 164(1):53-60.
38. Pande V, Ramos MJ. Nuclear factor kappa B: a potential target for anti-HIV chemotherapy. Curr Med Chem 2003, 10(16):1603-1615.
39. Cameron A, Read J, Tranter R, Winter VJ, Sessions RB, Brady RL, Vivas L, Easton A, Kendrick H, Croft SL, Barros D, Lavandera JL, Martin JJ, Risco F, García-Ochoa S, Gamo FJ, Sanz L, Leon L, Ruiz JR, Gabarró R, Mallo A, Gómez de las Heras F. Identification and activity of a series of azole-based compounds with lactate dehydrogenase-directed anti-malarial activity. J Biol Chem 2004, 279(30):31429-31439.
40. Huy NT, Kamei K, Kondo Y, Serada S, Kanaori K, Takano R, Tajima K, Hara S. Effect of antifungal azoles on the heme detoxification system of malarial parasite. J Biochem 2002, 131(3):437-444.
41. Pfaller MA, Krogstad DJ. Imidazole and polyene activity against chloroquine-resistant Plasmodium falciparum. J Infect Dis 1981, 144(4):372-375.
42. Pfaller MA, Segal JJ, Krogstad DJ. Activity of ketoconazole and its deacyl derivative against Plasmodium falciparum and Candida isolates. Antimicrob Agents Chemother 1982, 22(5):917-919.
43. Saliba KJ, Kirk K. Clotrimazole inhibits the growth of Plasmodium falciparum in vitro. Trans R Soc Trop Med Hyg 1998, 92(6):666-667.
44. Woodruff AW, Dickinson CJ. Use of dexamethasone in cerebral malaria. Br Med J 1968, 3(5609):31-32.
45. Rees P. Dexamethasone deleterious in cerebral malaria. Br Med J (Clin Res Ed) 1982, 285(6351):1357.
46. Warrell DA, Looareesuwan S, Warrell MJ, Kasemsarn P, Intaraprasert R, Bunnag D, Harinasuta T. Dexamethasone proves deleterious in cerebral malaria. A double-blind trial in 100 comatose patients. N Engl J Med 1982, 306(6):313-319.
47. Ganesh D, Fuehrer HP, Starzengruber P, Swoboda P, Khan WA, Reismann JA, Mueller MS, Chiba P, Noedl H. Antiplasmodial activity of flavonol quercetin and its analogues in Plasmodium falciparum: evidence from clinical isolates in Bangladesh and standardized parasite clones. Parasitol Res 2012, 110(6):2289-2295.
48. Martiney JA, Cerami A, Slater AF. Verapamil reversal of chloroquine resistance in the malaria parasite Plasmodium falciparum is specific for resistant parasites and independent of the weak base effect. J Biol Chem 1995, 270(38):22393-22398.
49. Paciorkowski A, Dai WW, Cerami A, Berger BJ. Synergism of cimetidine with anti-malarial agents. J Parasitol 1997, 83(5):960-963.
50. Ginsburg H, Geary TG. Current concepts and new ideas on the mechanism of action of quinoline-containing antimalarials. Biochem Pharmacol 1987, 36(10):1567-1576.
51. Foote SJ, Thompson JK, Cowman AF, Kemp DJ. Amplification of the multidrug resistance gene in some chloroquine-resistant isolates of P. falciparum. Cell 1989, 57(6):921-930.
52. Gardner FH, Helmer RE. Aminocaproic acid. Use in control of hemorrhage in patients with amegakaryocytic thrombocytopenia. JAMA 1980, 243(1):35-37.
53. Fujiyoshi N, Deitch EA, Feketeova E, Lu Q, Berezina TL, Zaets SB, Machiedo GW, Xu DZ, Hasko G. Amiloride combined with small-volume resuscitation with hypertonic saline is superior in ameliorating trauma-hemorrhagic shock-induced lung injury in rats to the administration of either agent alone. Crit Care Med 2005, 33(11):2592-2598.
54. Cuyler WK, Hamblem EC, Davis CD. Diethylstilbestrol for hemostasis in functional uterine hemorrhage. J Clin Endocrinol Metabol 1942, 2:438-441.